147 related articles for article (PubMed ID: 38358899)
1. Real-world comparative effectiveness of dalteparin and enoxaparin for venous thromboembolism prophylaxis.
Di Mauro AL; Austin LJ; Zande J; Winckel K; Neale R; De Guzman KR
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):101-107. PubMed ID: 38358899
[TBL] [Abstract][Full Text] [Related]
2. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
Carson W; Schilling B; Simons WR; Parks C; Choe Y; Faria C; Powers A
J Pharm Pract; 2012 Apr; 25(2):180-9. PubMed ID: 21987527
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
[TBL] [Abstract][Full Text] [Related]
5. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
6. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
7. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
8. Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.
Worley S; Short C; Pike J; Anderson D; Douglas JA; Thompson K
J Spinal Cord Med; 2008; 31(4):379-87. PubMed ID: 18959355
[TBL] [Abstract][Full Text] [Related]
9. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.
Miano TA; Cuker A; Christie JD; Martin N; Smith B; Makley AT; Guo W; Hennessy S
Chest; 2018 Jan; 153(1):133-142. PubMed ID: 28823757
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.
Comp P; Happe LE; Sarnes M; Farrelly E
Am J Orthop (Belle Mead NJ); 2008 Sep; 37(9):470-5. PubMed ID: 18982184
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
16. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Happe LE; Farrelly EM; Stanford RH; Sarnes MW
J Thromb Thrombolysis; 2008 Oct; 26(2):125-31. PubMed ID: 18034323
[TBL] [Abstract][Full Text] [Related]
17. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
18. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.
Dranitsaris G; Jelincic V; Choe Y
Clin Appl Thromb Hemost; 2012 Jun; 18(3):233-42. PubMed ID: 22387576
[TBL] [Abstract][Full Text] [Related]
19. Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Changolkar A; Menditto L; Shah M; Puto K; Farrelly E
Am J Health Syst Pharm; 2014 Apr; 71(7):562-9. PubMed ID: 24644116
[TBL] [Abstract][Full Text] [Related]
20. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.
Kher A; Samama MM
J Thromb Haemost; 2005 Mar; 3(3):473-81. PubMed ID: 15748236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
